BMS-582949 acts as a dual action kinase inhibitor. It inhibits both p38 mitogen-activated protein kinase (p38 MAPK) activity and activation of p38. As a blocking agent for activation of p38 kinase BMS-582949 appeared to be well suited to resist such cellular responses that would drive p38 activation more strongly. BMS-582949 is in Phase II clinical trials for the treatment of rheumatoid arthritis, psoriasis, and atherosclerosis.

GW 590735 is a selective and potent agonist of peroxisome proliferator-activated receptor alpha (PPARα), a ligand-activated transcription factor that plays a key role in lipid homeostasis. Activation of PPARα results in increased clearance of triglyceride (TG) rich very low-density lipoprotein. GW 590735 was in phase II clinical trial for the treatment of dyslipidemia, but that study was discontinued.

Epiroprim (Ro 11-8958) is a dihydrofolate reductase inhibitor. Epiroprim displayed activity against a broad range of bacteria including mycobacteria, staphylococci, enterococci, pneumococci, and streptococci as well as against Toxoplasma gondii. Epiroprim development has been discontinued.

Sulfaclorazole is a benzenesulfonamide derivative patented by Farbwerke Hoechst A.-G. as an antibacterial agent that active against Streptococcus pyogenes.

Besunide was studied as a diuretic agent.

Besulpamide has been developed as a diuretic agent.

Etiracetam is a nootropic agent. (-)-(S) enantiomer of etiracetam levetiracetam (Keppra®) is used for the treatment of epilepsy.

Sulfiram (also known as monosulfiram) is a sulfide derivative patented by L. Givaudan & Cie. S. A. as effective anti-parasitic medicine used for the treatment and prevention of scabies and other skin related problems like itching, skin irritation, and inflammation. Sulfiram is a very weak inhibitor of aldehyde dehydrogenase. Sulfiram is usually sold as a solution or medicated soap, sometimes in combination with benzyl benzoate. Sulfiram is now rarely used, but, as of 2015, is still available in Brazil, India, and South Africa.

Pipradimadol is a 4.4-disubstituted piperidine derivative which demonstrates, in animal experiments, effects typical for certain antidepressant and antiserotonin drugs. Pipradimadol is the central serotonin antagonist. Pipradimadol exhibits antinociceptive properties also. Behavioral tests reflect overall sedation after pipradimadol, decreased rectal temperature and locomotor activity; cataleptic effects of tetrabenazine are antagonized and noradrenaline as well as dopamine reuptake in vitro are slightly inhibited. Homovanillic acid, a metabolite of dopamine is strongly increased after pipradimadol in rat striatum. Pipradimadol was used as analgesic agent.